in

Second primary malignancies represent small proportion of adverse events after CAR T-cell therapy

Second primary malignancies represent small proportion of adverse events after CAR T-cell therapy

Second primary malignancies (SPMs) represent a small proportion of adverse events (AEs) reported by patients receiving chimeric antigen receptor T-cell (CAR T-cell) therapy, according to a letter to the editor published online March 14 in Blood.


Posted by Editor

US Fashion Lobby Calls for Release of Jailed Bangladesh Apparel Workers

US Fashion Lobby Calls for Release of Jailed Bangladesh Apparel Workers

Martin Lewis revealed a hack to get cheap EasyJet flights

Martin Lewis shares ‘urgent heads up’ to get cheap flights and save hundreds